

“Bone marrow failure syndromes” focus on MDS

Uwe Platzbecker

University Hospital Leipzig

Management of Myelodysplastic neoplasms (MDS) requires a personalized approach, with a focus on improving quality of life and extending lifespan. The International Prognostic Scoring System-Revised (IPSS-R) and the molecular International Prognostic Scoring System (IPSS-M) are key tools for risk stratification and management of MDS. They provide a framework for predicting survival and risk of transformation to acute myeloid leukemia. However, a major challenge in MDS management remains the limited therapeutic options available, especially after failure of first-line therapies. In lower-risk MDS, the failure of erythropoietin-stimulating agents (ESAs) often leaves few alternatives, while in higher-risk MDS, the prognosis after hypomethylating agents (HMAs) failure is dismal. This highlights the urgent need for novel, more personalized therapeutic approaches. In this presentation, I will discuss emerging novel therapeutic approaches in the treatment of MDS. Several new therapeutic targets are currently being evaluated, offering hope for improved management of MDS in the future.